Keywords
Last Name
Institution

JI YUAN WU

TitleInstructor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address6767 Bertner St
Houston TX 77030-2603
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152; PMCID: PMC4055926.
    2. Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorg Med Chem. 2013 Feb 15; 21(4):932-9. PMID: 23294827.
      View in: PubMed
    3. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther. 2011 Nov; 10(11):2094-103. PMID: 21903608.
      View in: PubMed
    4. Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. Leukemia. 2010 Apr; 24(4):869-72. PMID: 20111070; PMCID: PMC4677994.
    5. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008 Jul 2; 100(13):926-39. PMID: 18577747; PMCID: PMC2902818.
    6. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008 Apr 1; 111(7):3821-9. PMID: 18235045; PMCID: PMC2275035.
    7. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15; 109(8):3470-8. PMID: 17202319.
      View in: PubMed
    8. Klostergaard J, Leroux ME, Auzenne E, Khodadadian M, Spohn W, Wu JY, Donato NJ. Hyperthermia engages the intrinsic apoptotic pathway by enhancing upstream caspase activation to overcome apoptotic resistance in MCF-7 breast adenocarcinoma cells. J Cell Biochem. 2006 May 15; 98(2):356-69. PMID: 16440323.
      View in: PubMed
    9. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M, Shishodin S. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004 Jan 15; 64(2):672-7. PMID: 14744784.
      View in: PubMed
    10. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003 Jan 15; 101(2):690-8. PMID: 12509383.
      View in: PubMed
    11. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 2001 May 1; 97(9):2846-53. PMID: 11313280.
      View in: PubMed
    12. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1204-13. PMID: 11350885.
      View in: PubMed
    13. Wright SE, Kilinski L, Talib S, Lowe KE, Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS, Philip R. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother. 2000 Jan; 23(1):2-10. PMID: 10687132.
      View in: PubMed
    14. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000 Jan; 6(1):260-70. PMID: 10656457.
      View in: PubMed
    15. Erratum. Cancer Research. 64:2306.
    16. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 7:39595-39608.
    17. Expansion of cytolytic effector cells from a breast cancer patient by stimulation with mucin peptide and antigen presenting cells. FASEB Journal. 10.
    18. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.
    19. At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells. Journal of Immunology. 196:4400-4409.
    WU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description